US FDA accepts resubmission of Amgen's Prolia
This article was originally published in Scrip
Executive Summary
The US FDA has accepted a resubmission of Amgen's bone drug Prolia (denosumab) for the treatment of postmenopausal osteoporosis (PMO) and set a PDUFA date of July 25th, 2010. After disappointing drug sales for Amgen in 2009, analysts are increasingly looking to the drug to provide the company with a much needed life float.